Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma

Makita, Shinichi; Hosoba, Rika; Tobinai, Kensei

doi:10.1080/14740338.2020.1802424

Cited by 7 publications

(3 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zanubrutinib is a second-generation BTK inhibitor, which was approved by the US FDA to treat relapsed/refractory Mantle-Cell Lymphoma (MCL) in 2019 ( 3 , 7 ). Compared with ibrutinib, it has higher BTK selectivity and exhibits less off-target inhibition of other tyrosine kinases ( 7 , 10 ). In two phase II studies of zanubrutinib, major bleeding was reported in 2 out of 85 patients (2.3%), and 2 out of 91 patients (2.2%) patients, respectively ( 11 , 12 ).…”

Section: Discussionmentioning

confidence: 99%

Case Report: Intraocular Hemorrhage in a Primary Vitreoretinal Lymphoma Patient Treated With Zanubrutinib

et al. 2022

View full text Add to dashboard Cite

PurposeTo report a case of primary vitreoretinal lymphoma (PVRL) treated with oral zanubrutinib, who had bilateral intraocular hemorrhage after intravitreal injection of methotrexate (MTX).Case reportA 69-year-old Chinese female presented with vision decrease in both eyes. After diagnostic vitrectomy, the patient was diagnosed as PVRL in both eyes, and was treated with intravenous rituximab, oral zanubrutinib and bilateral intravitreal MTX. There were bilateral anterior chamber and vitreous hemorrhage after the fourth intravitreal MTX combined with paracentesis. After discontinuation of zanubrutinib, vitrectomy and silicon oil tamponade were performed on the left eye, and the blood in the right eye was absorbed.ConclusionBleeding is a major concern in the use of zanubrutinib. It is suggested that drugs be held for a few days prior to procedures and surgeries.

show abstract

Section: Discussionmentioning

confidence: 99%

Case Report: Intraocular Hemorrhage in a Primary Vitreoretinal Lymphoma Patient Treated With Zanubrutinib

et al. 2022

View full text Add to dashboard Cite

show abstract

“…When needed, blood glucose levels were controlled with hyperglycemia medications. Hyperglycemia during copanlisib is caused by inhibition of PI3Kα, which is involved in insulin-like growth factor signaling [ 17 ]. It is generally asymptomatic and can usually be managed with intravenous or oral fluids.…”

Section: Discussionmentioning

confidence: 99%

Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study

et al. 2022

Self Cite

View full text Add to dashboard Cite

The safety, efficacy, and pharmacokinetics of copanlisib were evaluated in this phase Ib/II study in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL). The primary endpoint was safety at the recommended dose; efficacy endpoints included objective response rate (ORR), progression-free survival (PFS), and overall survival. In phase Ib, patients received copanlisib 45 mg intravenously on days 1, 8, and 15 of a 28-day cycle, and when tolerated, consecutive patients received copanlisib 60 mg. As no dose-limiting toxicities occurred at the 45 mg (n = 3) or 60 mg (n = 7) dose in phase Ib, the recommended dose for Japanese patients was determined to be 60 mg, and this dose was used in phase II (n = 15). Although all patients experienced at least one treatment-emergent adverse event (TEAE), with hyperglycemia being the most common AE, no AE-related deaths were reported. The ORR was 68.0% (17/25 patients), median PFS was 302 (95% CI 231–484) days, and the duration of response was 330 (range 65–659) days. The pharmacokinetic properties of copanlisib were similar between Japanese and non-Japanese patients. Overall, copanlisib 60 mg had an acceptable safety profile and showed promising antitumor activity in Japanese patients with relapsed/refractory indolent NHL.

show abstract

“…In the case of lymphoma, similar to other cancer cells, many of the proteins associated with the survival, angiogenesis, and metastasis of cancer cells are hyperactivated. To suppress the hyperactivation, specific proteins in lymphoma are targeted namely Bruton tyrosine kinase, PI3K, HDACs, and proteasomal system proteins [17].…”

Section: Small Molecule Inhibitors In Lymphomamentioning

confidence: 99%

Drugs and Drug Candidates for the Treatment of Lymphoma

Coşkun¹,

Tutar²,

Abay³

et al. 2022

Lymphoma

View full text Add to dashboard Cite

Cancer is the biggest health problem worldwide due to its high mortality rate. Lymphoma is defined as a group of malignant diseases that is caused by clonal proliferation of lymphocytes and is classified under two major groups: Hodgkin lymphoma and non-Hodgkin lymphoma. Genetic predisposition and some environmental factors constitute risk factors. Symptoms of the disease include unexplained fever, swelling of lymph glands, swollen abdomen, tiredness, loss of appetite, frequent infections, and weight loss. Positron emission tomography (PET) and computed tomography (CT) scans, along with MRI, are widely used for the diagnosis of lymphoma. Advanced blood and lymph node biopsy tests are used to evaluate treatment effect on blood cells and to confirm the diagnosis of lymphoma, respectively. Current treatment options include chemotherapy, radiotherapy, and bone marrow/stem cell transplantation. Development of new treatment options for cancer medications includes small molecules and monoclonal antibodies for immunotherapy. In addition, the discovery of new phytochemical agents used in complementary and alternative medicine adds perspective to the treatment of lymphoma.

show abstract

Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma

Cited by 7 publications

References 116 publications

Case Report: Intraocular Hemorrhage in a Primary Vitreoretinal Lymphoma Patient Treated With Zanubrutinib

Case Report: Intraocular Hemorrhage in a Primary Vitreoretinal Lymphoma Patient Treated With Zanubrutinib

Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study

Drugs and Drug Candidates for the Treatment of Lymphoma

Contact Info

Product

Resources

About